Rohto Pharmaceutical Co Ltd

Rohto Pharmaceutical maintains a strong liquidity position with a current ratio of 2.3 and cash and equivalents of ¥77.16 billion, which supports operational flexibility and debt servicing. The company's liquidity FPT score of 0.85 indicates a low risk of short-term financial distress, supported by free cash flow of ¥26.46 billion and operating cash flow of ¥37.13 billion. Profitability metrics show a return on equity of 11.92% and return on assets of 7.35%, both exceeding the industry median for Pharmaceuticals. Operating income of ¥36.87 billion and net income of ¥31.01 billion reflect strong cost control and pricing power in its core markets. The company's revenue is concentrated in Japan, with disclosed segments including pharmaceuticals and cosmetics. No material geographic diversification is reported, and the top product categories account for the majority of revenue. This concentration may expose Rohto to regulatory and market-specific risks in Japan. Outlook data indicates a 3.2% year-over-year revenue growth for the current fiscal year, with a projected 2.8% increase in the following year. This growth is supported by continued demand for over-the-counter medications and expansion in the cosmetics segment. Risk assessment shows a low probability of dilution and no immediate liquidity concerns. The debt-to-equity ratio of 0.25 suggests a conservative capital structure, and no recent equity issuance or ATM programs have been disclosed. The company's risk score remains low, with no filing-based red flags detected. Recent filings and transcripts highlight Rohto's focus on R&D for new drug formulations and expansion in the cosmetics market. No material legal or regulatory issues were disclosed in the latest 10-K or investor presentations.